Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
received:
26
11
2020
revised:
16
02
2021
accepted:
30
03
2021
pubmed:
11
4
2021
medline:
25
2
2022
entrez:
10
4
2021
Statut:
ppublish
Résumé
Recent genome-wide association meta-analysis for melanoma doubled the number of previously identified variants. We assessed the performance of an updated polygenic risk score (PRS) in a population of older individuals, where melanoma incidence and cumulative ultraviolet radiation exposure is greatest. We assessed a PRS for cutaneous melanoma comprising 55 variants in a prospective study of 12 712 individuals in the ASPirin in Reducing Events in the Elderly Trial. We evaluated incident melanomas diagnosed during the trial and prevalent melanomas diagnosed preenrolment (self-reported). Multivariable models examined associations between PRS as a continuous variable (per SD) and categorical (low-risk [0%-20%], medium-risk [21%-80%], high-risk [81%-100%] groups) with incident melanoma. Logistic regression examined the association between PRS and prevalent melanoma. At baseline, mean participant age was 75 years; 55.0% were female, and 528 (4.2%) had prevalent melanomas. During follow-up (median = 4.7 years), 120 (1.0%) incident cutaneous melanomas occurred, 98 of which were in participants with no history. PRS was associated with incident melanoma (hazard ratio = 1.46 per SD, 95% confidence interval [CI] = 1.20 to 1.77) and prevalent melanoma (odds ratio [OR] = 1.55 per SD, 95% CI = 1.42 to 1.69). Participants in the highest-risk PRS group had increased risk compared with the low-risk group for incident melanoma (OR = 2.51, 95% CI = 1.28 to 4.92) and prevalent melanoma (OR = 3.66, 95% CI = 2.69 to 5.05). When stratifying by sex, only males had an association between the PRS and incident melanoma, whereas both sexes had an association between the PRS and prevalent melanoma. A genomic risk score is associated with melanoma risk in older individuals and may contribute to targeted surveillance.
Sections du résumé
BACKGROUND
Recent genome-wide association meta-analysis for melanoma doubled the number of previously identified variants. We assessed the performance of an updated polygenic risk score (PRS) in a population of older individuals, where melanoma incidence and cumulative ultraviolet radiation exposure is greatest.
METHODS
We assessed a PRS for cutaneous melanoma comprising 55 variants in a prospective study of 12 712 individuals in the ASPirin in Reducing Events in the Elderly Trial. We evaluated incident melanomas diagnosed during the trial and prevalent melanomas diagnosed preenrolment (self-reported). Multivariable models examined associations between PRS as a continuous variable (per SD) and categorical (low-risk [0%-20%], medium-risk [21%-80%], high-risk [81%-100%] groups) with incident melanoma. Logistic regression examined the association between PRS and prevalent melanoma.
RESULTS
At baseline, mean participant age was 75 years; 55.0% were female, and 528 (4.2%) had prevalent melanomas. During follow-up (median = 4.7 years), 120 (1.0%) incident cutaneous melanomas occurred, 98 of which were in participants with no history. PRS was associated with incident melanoma (hazard ratio = 1.46 per SD, 95% confidence interval [CI] = 1.20 to 1.77) and prevalent melanoma (odds ratio [OR] = 1.55 per SD, 95% CI = 1.42 to 1.69). Participants in the highest-risk PRS group had increased risk compared with the low-risk group for incident melanoma (OR = 2.51, 95% CI = 1.28 to 4.92) and prevalent melanoma (OR = 3.66, 95% CI = 2.69 to 5.05). When stratifying by sex, only males had an association between the PRS and incident melanoma, whereas both sexes had an association between the PRS and prevalent melanoma.
CONCLUSIONS
A genomic risk score is associated with melanoma risk in older individuals and may contribute to targeted surveillance.
Identifiants
pubmed: 33837773
pii: 6220042
doi: 10.1093/jnci/djab076
pmc: PMC8921762
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
1379-1385Subventions
Organisme : NCI NIH HHS
ID : K07 CA218377
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Nat Genet. 2011 Oct 09;43(11):1114-8
pubmed: 21983785
Med J Aust. 2018 Apr 2;208(6):265-269
pubmed: 29614940
Br J Dermatol. 2020 May;182(5):1262-1268
pubmed: 31378928
Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1450-63
pubmed: 24895414
Br J Dermatol. 2019 Dec;181(6):1146-1155
pubmed: 30908599
Int J Oncol. 2018 Apr;52(4):1071-1080
pubmed: 29532857
J Invest Dermatol. 2016 Mar;136(3):690-695
pubmed: 27015455
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Aust N Z J Public Health. 2014 Feb;38(1):35-8
pubmed: 24494943
N Engl J Med. 2018 Oct 18;379(16):1499-1508
pubmed: 30221596
JAMA Dermatol. 2020 May 1;156(5):553-560
pubmed: 32211827
Oncotarget. 2017 Mar 14;8(11):17586-17592
pubmed: 28212542
N Engl J Med. 2018 Oct 18;379(16):1509-1518
pubmed: 30221597
J Natl Cancer Inst. 2003 Jun 4;95(11):806-12
pubmed: 12783935
Hum Mol Genet. 2018 Dec 1;27(23):4145-4156
pubmed: 30060076
J Am Acad Dermatol. 2018 Jul;79(1):36-41.e10
pubmed: 29499294
Nat Genet. 2011 Oct 09;43(11):1108-13
pubmed: 21983787
N Engl J Med. 2018 Oct 18;379(16):1519-1528
pubmed: 30221595
Nat Genet. 2016 Oct;48(10):1284-1287
pubmed: 27571263
J Clin Oncol. 2013 Jun 20;31(18):2337-46
pubmed: 23690423
PLoS Genet. 2019 Jun 13;15(6):e1008202
pubmed: 31194742
J Cancer. 2011;2:538-43
pubmed: 22084644
J Invest Dermatol. 2018 Dec;138(12):2617-2624
pubmed: 29890168
J Med Genet. 2021 Nov;58(11):760-766
pubmed: 32994281
Biostatistics. 2015 Jan;16(1):143-54
pubmed: 25027274
Hum Mol Genet. 2011 Dec 15;20(24):5012-23
pubmed: 21926416
Genet Med. 2009 Apr;11(4):265-78
pubmed: 19265718
Pigment Cell Melanoma Res. 2013 Jan;26(1):128-35
pubmed: 23095171
Nat Genet. 2020 May;52(5):494-504
pubmed: 32341527
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Ann Oncol. 2008 Mar;19(3):583-9
pubmed: 17974555
Contemp Clin Trials. 2013 Nov;36(2):555-64
pubmed: 24113028
PLoS One. 2013 Dec 31;8(12):e85642
pubmed: 24392023
Cancer. 2008 Apr 15;112(8):1795-804
pubmed: 18306371
J Natl Cancer Inst. 2021 Mar 1;113(3):258-265
pubmed: 32778876
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Genome Res. 2007 Oct;17(10):1520-8
pubmed: 17785532